Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
40 hedge funds and large institutions have $947M invested in Centessa Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 16 closing their positions.
9.08% more ownership
Funds ownership: 54.23% → 63.31% (+9.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
9% less capital invested
Capital invested by funds: $1.05B → $947M (-$97.9M)
20% less funds holding
Funds holding: 50 → 40 (-10)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
+$169M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$47.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$15.1M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$8.9M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.6M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$11.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.84M |
| 4 |
Millennium Management
New York
|
-$4.38M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.89M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Two Sigma Investments
New York
| – | -$222K | -9,973 | Closed |
|
52
Geode Capital Management
Boston,
Massachusetts
| – | -$211K | -9,513 | Closed |
|
53
BlackRock
New York
| – | -$110K | -4,992 | Closed |
|
|
PCM
54
Pinz Capital Management
New York
| – | -$20K | -900 | Closed |
|
|
SOW
55
State of Wyoming
Cheyenne,
Wyoming
| – | +$476 | +23 | New |
|
CNTA Hedge Fund Activity: Q3 2021 in Review
40 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q3 2021, worth a combined $947M — down 9.4% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CNTA and 6 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 13 added.
The largest buyer was General Atlantic, adding an estimated $169M. The largest seller was Wellington Management Group, exiting entirely with an estimated $24.6M sold.
- 40 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q3 2021, down from 50 in Q2 2021.
- Funds reported $947M of Centessa Pharmaceuticals stock for Q3 2021, down 9.4% quarter-over-quarter.
- 6 funds opened new Centessa Pharmaceuticals positions in Q3 2021 and 16 closed out, a net change of -10 holders.
- The largest Centessa Pharmaceuticals buyer in Q3 2021 was General Atlantic, an estimated $169M added.
- The largest Centessa Pharmaceuticals seller in Q3 2021 was Wellington Management Group, an estimated $24.6M sold.
Based on aggregated 13F filings for Q3 2021.